Published in Br J Cancer on September 18, 2006
Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer (2008) 1.32
Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer (2010) 1.00
Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice. Radiat Oncol (2016) 0.88
Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol (2010) 0.88
Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res (2009) 0.84
High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer. Eur J Nucl Med Mol Imaging (2015) 0.81
Safety and outcome of external beam radiation and neutron brachytherapy in elderly patients with esophageal squamous cell cancer. J Contemp Brachytherapy (2017) 0.78
Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer (2013) 0.76
Salvage endoscopic resection as a treatment for locoregional failure or recurrence following chemoradiotherapy or radiotherapy for esophageal cancer. Oncol Lett (2016) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Esophageal cancer. N Engl J Med (2003) 15.23
Cancer statistics, 2002. CA Cancer J Clin (2002) 10.79
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med (1992) 7.40
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol (2002) 6.74
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol (2005) 5.19
Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut (1982) 3.68
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol (2006) 1.97
Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol (2000) 1.92
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol (1999) 1.84
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res (2002) 1.78
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer (2002) 1.34
Chemotherapy in esophageal cancer. Semin Oncol (1999) 1.33
Gastrointestinal cancers in Europe. Aliment Pharmacol Ther (2003) 1.23
Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer (1999) 1.10
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol (2003) 1.07
Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res (1997) 1.02
Application of the triangular test to phase II cancer clinical trials. Stat Med (1990) 0.98
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer (1999) 0.87
Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer (1990) 0.87
Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res (1999) 0.85
The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer (2002) 0.83
Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Cancer (1996) 0.80
Clinical and pathological evaluation of response to chemotherapy in patients with esophageal carcinoma. Am J Clin Oncol (1983) 0.77
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer (1994) 6.31
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer (2007) 5.38
Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology (1994) 2.62
Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg (2012) 2.24
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol (2012) 1.82
Intestinal lymphangiectasia: lack of efficacy of antiplasmin therapy? Gastroenterology (1991) 1.76
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol (2002) 1.61
Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther (2006) 1.46
Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol (2001) 1.46
Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol. Br J Surg (2003) 1.45
[Cystic tumors and endocrine tumor of the pancreas. An unusual association]. Gastroenterol Clin Biol (1993) 1.45
Postoperative management of stage II/III colon cancer: a decision analysis. Gastroenterology (1999) 1.45
Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol (2008) 1.44
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol (2002) 1.44
Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology (1992) 1.43
Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol (2008) 1.43
Abdominal radiotherapy is a cause for chronic pancreatitis. Gastroenterology (1993) 1.40
The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg (1987) 1.40
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med (2012) 1.39
Control of pelvic symptoms in patients with rectal cancer and synchronous metastases. Gastroenterol Clin Biol (2009) 1.38
Respiratory response to CO2 in patients with chronic obstructive pulmonary disease in acute respiratory failure. Eur Respir J (1993) 1.38
[Black esophagus. Three new cases]. Gastroenterol Clin Biol (1993) 1.37
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol (1998) 1.34
Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer (2008) 1.32
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology (1999) 1.29
Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) (1999) 1.26
Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat (2010) 1.23
Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg (2000) 1.22
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer (2009) 1.22
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer (2007) 1.19
Immunological study in primary intestinal lymphangiectasia. Digestion (1994) 1.19
Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol (1994) 1.13
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol (2012) 1.11
[Whole gut irrigation with isotonic mannitol solution in the treatment of gastrointestinal bleeding due to cirrhosis: a controlled study (author's transl)]. Gastroenterol Clin Biol (1978) 1.11
Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol (1996) 1.10
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol (2001) 1.08
Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology (2009) 1.08
Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology (1988) 1.08
Lugol chromo-endoscopy versus narrow band imaging for endoscopic screening of esophageal squamous-cell carcinoma in patients with a history of cured esophageal cancer: a feasibility study. Dis Esophagus (2011) 1.07
1,25-dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues. Cancer Lett (1994) 1.06
Pseudoaneurysms and bleeding pseudocysts in chronic pancreatitis: radiological findings and contribution to diagnosis in 8 cases. Gastrointest Radiol (1990) 1.06
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer (2000) 1.05
Radiopaque markers transit and anorectal manometry in 16 patients with multiple sclerosis and urinary bladder dysfunction. Dis Colon Rectum (1987) 1.03
Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. J Med Genet (2004) 1.03
Identification of novel germline hMLH1 mutations including a 22 kb Alu-mediated deletion in patients with familial colorectal cancer. Cancer Res (1996) 1.02
Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol (1998) 1.02
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1996) 1.02
Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer (2010) 1.00
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol (1996) 1.00
Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest (2000) 0.99
Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging (2013) 0.99
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. Br J Cancer (2006) 0.99
Chemoreflex ventilatory response to CO 2 in man at low and high altitudes. Respir Physiol (1972) 0.98
Cervical lymph nodes from an unknown primary tumor in 190 patients. Am J Surg (1990) 0.98
Comparison between endoscopic and surgical sampling for the measurement of potential doubling time in colorectal cancer. Cytometry (1997) 0.97
Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol (1995) 0.96
Prior chemoradiotherapy is associated with a higher life-threatening complication rate after palliative insertion of metal stents in patients with oesophageal cancer. Aliment Pharmacol Ther (2006) 0.96
[Stereotactic body radiation therapy for liver primary and metastases: the Lille experience]. Cancer Radiother (2011) 0.96
Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution. Am J Surg Pathol (2001) 0.95
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol (2002) 0.94
Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum (2001) 0.94
How accurate is clinical examination in diagnosing and quantifying pelvirectal disorders? A prospective study in a group of 50 patients complaining of defecatory difficulties. Dis Colon Rectum (1993) 0.94
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br J Cancer (2009) 0.94
Dyschezia and rectocele--a marriage of convenience? Physiologic evaluation of the rectocele in a group of 52 women complaining of difficulty in evacuation. Dis Colon Rectum (1993) 0.93
Yogurt and fermented-then-pasteurized milk: effects of short-term and long-term ingestion on lactose absorption and mucosal lactase activity in lactase-deficient subjects. Am J Clin Nutr (1989) 0.93
Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer (2013) 0.92
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br J Cancer (2010) 0.92
Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases. Gut (1997) 0.92
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol (2002) 0.92
A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. Eur J Gastroenterol Hepatol (2001) 0.91
Sentinel node mapping in colon carcinoma: in-vivo versus ex-vivo approach. Eur J Surg Oncol (2006) 0.91